Mechanism of Action

• Antagonizes protease-activated receptor PAR-1, which is used by thrombin for platelet activation

Half-Life

• 3-4 days

Excretion

• Feces (58%) & Urine (25%)

Dosing – Adult

• Oral: 2.08 mg daily

Dosing – Pediatric

• Safety and efficacy in pediatric patients not established

Onset & Duration of IPA

• Onset: ≥80% inhibition of thrombin receptor peptide (TRAP)-induced platelet aggregation within 1 week
• Duration: inhibition of 50% (TRAP)-induced platelet aggregation at 4 weeks